Recent Updates
Recently added Catalysts
NSPR Positive Sentiment

InspireMD to Participate in Upcoming November Investor Conferences

Key Takeaway: InspireMD, a developer of the CGuard™ Embolic Prevention Stent System, has announced participation in three investor conferences this November. CEO Marvin Slosman will represent the company at the Wolfe Research Healthcare Conference, Canaccord Genuity MedTech Forum, and the Piper 35th Annual Healthcare Conference. Live webcasts of these presentations will be made available on the company's website, reflecting InspireMD's commitment to investor communication and transparency.
Price reaction · baseline $3.77 (2023-11-01 close) · hit after-hours · 1 other NSPR headline(s) in the window, move may be shared
day 0 close
-11.4%
day 1
-8.6%
day 3 · peak
-14.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • InspireMD's CEO will participate in multiple prestigious investor conferences.
  • The company aims to establish its products as industry standards.
  • The presence at investor conferences indicates growing interest and engagement opportunities.

Full Press Release Details

TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November:
Wolfe Research Healthcare Conference
Wednesday, November 15, 2023
Fireside chat: 12:30pm ET
Canaccord Genuity MedTech, Diagnostics, Digital Health & Services Forum
Thursday, November 16, 2023
Investor one-on-one meetings only
Piper 35th Annual Healthcare Conference
Wednesday, November 29, 2023
Fireside chat: 8:00am ET
A live webcast of the presentations will be available in the News and Events section of the Company’s website at www.inspiremd.com/en/events/. Replays will be available on the website for 30 days.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Chief Financial Officer
Chuck Padala, Managing Director

Frequently Asked Questions

What is the CGuard™ system used for?

The CGuard™ Embolic Prevention Stent System treats carotid artery disease and prevents stroke.

When is InspireMD's participation in investor conferences?

InspireMD will participate in investor conferences on November 15, 16, and 29, 2023.

Where can I watch the investor conference presentations?

You can watch the live presentations on InspireMD's website under the News and Events section.

What technology does InspireMD utilize?

InspireMD uses its proprietary MicroNet® technology to enhance carotid stenting outcomes.

What is InspireMD's stock ticker?

InspireMD is listed on Nasdaq under the ticker symbol NSPR.

Last updated: Nov 2, 2023